Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn ...
WOMEN can wait up to 16 years to be diagnosed with a life-threatening condition dismissed as heavy periods. By contrast, it ...
Hemab Therapeutics Inc. COAG on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease ...
Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing ...
A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines ...
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 ...
Spark Biomedical today announced publication of a first-in-human study with Northwell Health's Feinstein Institutes for Medical Research. The study, published in Bioelectronic Medicine, shows Spark's ...
Routine dental procedures can be dangerous for haemophilia patients without proper planning. A review urges preventive care, ...
Here's What Other Cities Can Learn From Its Blueprint FFor most kids, childhood is measured by familiar defining events: pool ...
IF businessman Dominic Hadeed is not released from prison detention soon, his health could deteriorate to the point where he ...
The Hearty Soul on MSN
Your period blood is trying to tell you something - the biggest red flags to look out for
Abnormal period blood - in color, volume, or timing - can signal fibroids, adenomyosis, bleeding disorders, or infection. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results